Shire plc (SHPG) Shares are Down -4.53%

Shire plc (SHPG) has risen sharply, recording gains of 0.77% in the past 4 weeks. However, the stock has corrected -4.53% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 1.32% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 1.45% and the 50-Day Moving Average is 1.17%.The 200 Day SMA reached 6.49%


Shire plc (NASDAQ:SHPG): The stock opened in the green at $195.03 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $195.27 and a low of $193.23 for the day. The stock did not find buyers even at the lows and closed at $193.86 recording a loss of -0.49%. 1,440,838 shares exchanged hands during the trading day. The stock had closed at $193.86 in the previous days trading.

Shire plc (SHPG) : The most positive equity analysts on Shire plc (SHPG) expects the shares to touch $325, whereas, the least positive believes that the stock will trade at $186 in the short term. The company is covered by 11 Wall Street Brokerage Firms. The average price target for shares are $257.64 with an expected fluctuation of $36.47 from the mean.

Shire plc is a biopharmaceutical company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. The Company commercializes its products in the areas of Neuroscience, Gastrointestinal (GI), Rare Diseases and Other therapeutic areas. The Companys products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), BUCCOLAM, LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), REPLAGAL (agalsidase alfa), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), CINRYZE C1 esterase inhibitor (human), FOSRENOL (lanthanum carbonate), XAGRID/ AGRYLIN (anagrelide hydrochloride) and PLENADREN (modified release hydrocortisone).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.